Le Lézard
Classified in: Health, Science and technology
Subject: CCA

WELL Health to Announce First Quarter 2024 Financial Results on May 8, 2024


VANCOUVER, BC, May 6, 2024 /CNW/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX:?WHTCF) ("WELL" or the "Company"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal First Quarter 2024 financial results for the period ended?March 31, 2024, on Wednesday, May 8, 2024. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at?1:00 pm ET?(10:00 am PT). The call will be hosted by?Hamed Shahbazi, Chairman and Chief Executive Officer and?Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call.

Conference Call Participant Details

Date: Wednesday, May 8, 2024

Time: 1:00 PM ET / 10:00 AM PT

Local - Toronto: 416-764-8650

Local - Vancouver: 778-383-7413

North American Toll Free: +1-888-664-6383

International: +1-416-764-8650

Webcast URL: https://well.company/events/

WELL HEALTH TECHNOLOGIES CORP.

Per: "Hamed Shahbazi"

Hamed Shahbazi

Chief Executive Officer, Chairman and Director

About WELL Health Technologies Corp.

WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 34,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 165 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF". To learn more about WELL, please visit: www.well.company.

SOURCE WELL Health Technologies Corp.


These press releases may also interest you

18 mai 2024
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
MODULAR ATP Study of the mCRMtm System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

More news about Health...


News published on and distributed by: